NATACYN

Phase 3Small molecule

IIVIEW Therapeutics Inc.

NATACYN is one of 10 small molecule programs targeting Blepharitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

BlepharitisNot yet recruiting

BlepharitisPhase 3

Not yet recruiting

Competition

Competitive Landscape

11 competitors in Blepharitis

#DrugCompanyPhaseTrials

E-Mycin

AAzurity Pharmaceuticals

Approved

1 2

Tobrex

VViatris Specialty LLC

Levaquin

Stromectol

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Flagyl

Elidel

BBausch Health Americas, Inc.

Lotemax

1 8

Xdemvy

TTarsus Pharmaceuticals, Inc.

Approved

1 9

NATACYN

IIVIEW Therapeutics Inc.

Phase 3

1 10

Betadine

BBecton, Dickinson and Company

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

ApprovedNot yet recruiting

Blepharitis

NCT07856680

Q4 2027

Phase 2Not yet recruiting

Keratitis

NCT06463678

Clinical

Trials by Indication[1]

Keratitis1 trial

Trial to Evaluate the Efficacy And Safety of IVIEW-1201 In the Treatment of Fungal Keratitis

Not yet recruiting·IIVIEW Therapeutics Inc.·Phase 2·NCT06463678·60 enrolled

Blepharitis1 trial

Treatment of Fungal Blepharitis With Natacyn: A Prospective Interventional Study

Not yet recruiting·BBrent Kramer·Approved·NCT07856680·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for NATACYN. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NATACYN compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NATACYN. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — IVIEW Therapeutics Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: IIVIEW Therapeutics Inc.

NATACYN

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q4 2027

Trials by Indication[1]

Keratitis1 trial

Blepharitis1 trial

References

Drug Info

Quick Facts

Related News